

1 **Neutrophil gelatinase-associated lipocalin and Fibrinogen-to-albumin ratio are**
2 **indicators of nephropathy in adult steady state sickle cell disease patients: A**
3 **multicenter case-control study in Ghana.**

4 Stephen Twumasi^{1*}, Enoch Odame Anto^{1,2}, Christian Obirikorang³, Richard Kobina Dadzie
5 Ephraim⁴, Benedict Sackey^{1,5}, Vivian Paintsil^{6,8}, Richard Owusu Ansah⁷, Alfred Effah³, Allwell
6 Adofo Ayirebi¹, Angela Opoku⁶, Godfred Yawson Scott¹, Leslie Osei⁶, Joyce Duku⁹, Emmanuel
7 Asafo Adjei⁹, Lilian Antwi Boateng^{1,5*}

8 ¹Department of Medical Diagnostics, Faculty of Allied Health Sciences, College of Health
9 Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana

10 ²School of Medical and Health Sciences, Edith Cowan University, Joondalup Drive, Perth,
11 Australia

12 ³Department of Molecular Medicine, School of Medicine and Dentistry, Kwame Nkrumah
13 University of Science and Technology, Kumasi, Ghana

14 ⁴Department of Medical Laboratory Science, University of Cape Coast, Cape-Coast, Ghana

15 ⁵Laboratory Department, University Health Services, Kwame Nkrumah University of Science and
16 Technology, Kumasi, Ghana

17 ⁶Sickle Cell Unit, Komfo Anokye Teaching Hospital, Kumasi, Ghana

18 ⁷Genomic Laboratory, Faculty of Allied Health Sciences, College of Health Sciences, Kwame
19 Nkrumah University of Science and Technology, Kumasi, Ghana

20 ⁸Department of Child Health, School of Medical Sciences, Kwame Nkrumah University of
21 Science and Technology, Kumasi, Ghana

22 ⁹Sickle cell clinic, Kumasi south Hospital, Kumasi, Ghana

23 *Corresponding Authors: Stephen Twumasi (stwumasi7116@gmail.com)

24 Lilian Antwi Boateng (akosboak@yahoo.com)

25 **Abstract**

26 **Background:** Progressive renal failure is one of the main complications in sickle cell disease.
27 Neutrophil Gelatinase-Associated Lipocalin (NGAL) is present in gelatinase/tertiary granules of
28 neutrophils and it is a relatively newly recognized marker of nephropathy. Fibrinogen increases and
29 albumin decreases in inflammatory conditions like SCD. This study investigated the diagnostic roles
30 of NGAL and fibrinogen-to-albumin ratio in steady state adult sickle cell disease patients.

31 **Methods:** In this study, 104 sickle cell disease participants and 51 healthy subjects were analysed.
32 Participants' information was thoroughly documented using a structured questionnaire and patient
33 case records. To evaluate the hematobiochemical parameters, 5ml of venous blood was drawn
34 from each participant and a clean catch of mid-stream urine was collected from each participant.
35 Subjects with sickle cell disease were further classified as SCD nephropathy and SCD non-
36 nephropathy subjects based on reduced estimated Glomerular Filtration Rate (eGFR) and
37 microalbuminuria.

38 **Results:** Prevalence of nephropathy was 32.7% among adult steady state SCD patients. Significant
39 high levels of Urine Albumin-to-Creatinine Ratio (UACR), NGAL and fibrinogen-to-albumin ratio
40 (FAR) were seen in SCD patients with nephropathy compared to those without nephropathy
41 ($p < 0.001$). NGAL levels significantly increased along with increased urine albumin-to-creatinine
42 ratio ($r = 0.28, p < 0.005$) in both SCD with nephropathy and those without nephropathy. There was a
43 significant negative correlation between creatinine ($r = -0.90, p < 0.0005$), urea ($r = -0.50, p < 0.0005$)
44 and eGFR in SCD subjects. Similarly, a significant negative relationship existed between UACR
45 and eGFR ($r = -0.34, p < 0.0005$). Creatinine also had a significant positive correlation with UACR
46 ($r = 0.27, p < 0.005$ and urea ($r = 0.56, p < 0.0005$) in SCD subjects. NGAL was found to be a good
47 predictor of nephropathy in steady state SCD patients with $AUC = 0.742, p < 0.0001$ when compared

48 with creatinine and urea with AUC=0.618, $p=0.048$ and AUC=0.531, $p=0.647$ respectively.
49 However, FAR could not be used as a predictive marker since it had non-significant poor
50 performance (AUC=0.462, $p=0.536$).

51 **Conclusion:** NGAL as independent marker, is an early predictor of kidney disease as compared to
52 urea and creatinine. Fibrinogen-to-albumin ratio can be used to track nephropathy treatment in
53 steady state sickle cell disease patients since it is elevated in those with sickle cell nephropathy
54 compared to healthy individuals. These two markers can be added to the available array of test in
55 the management of nephropathy among steady SCD patients.

56 **Keywords**

57 Sickle cell disease, Sickle cell nephropathy, Serum neutrophil gelatinase- associated lipocalin,
58 Fibrinogen-to-albumin ratio, microalbuminuria

60 **Introduction**

61 Renal injury is a common consequence of sickle cell disease (SCD) caused by long-term anemia
62 and disrupted circulation through the medullar capillaries (1). Between 5% and 18% of sickle cell
63 disease patients get renal failure (2). Renal failure affects 4–21% of adult SCD patients due to
64 nephropathy in the United States (3). In Ghana, 39.6% of SCD children with nephropathy were
65 found to have CKD based on decreased eGFR (4). According to a study conducted in Ghana by
66 Ephraim *et al.*, (2015), the prevalence of CKD in the overall SCD population was found to be 39.2%,
67 with adults having a prevalence of 68.4% and children having a prevalence of 31.6% (5). The
68 detection of increasing renal impairment using conventional markers such as serum creatinine levels
69 (Cr), or creatinine clearance (Ccr) and urea are frequently deceptive. The serum creatinine, the
70 primary clinical tool for measuring renal function is insensitive for the detection of moderate

71 alterations in renal function and is affected by factors unrelated to renal activity, such as age, gender,
72 race, and lean muscle mass (6). The equations to estimate glomerular filtration rate do not present a
73 good correlation with laboratory measurements (7). The conventional renal function tests such as
74 serum creatinine, urea and glomerular filtration rate show abnormal results in SCD only when there
75 is extensive renal damage (8). There is a growing need to develop more sensitive markers for the
76 early detection of renal dysfunction in SCD patients since derangement of the conventional markers
77 would be late indicators of irreversible kidney damage.

78 Neutrophil Gelatinase-Associated Lipocalin (NGAL) is present in tertiary granules of activated
79 neutrophils. Kidney tubular cells may produce NGAL in response to various injuries. It is a relatively
80 newly recognized marker of nephropathy. NGAL was suggested to be a biomarker of acute kidney
81 injury (AKI) even in the setting of chronic kidney disease and has a strong association with
82 albuminuria(9). Following ischemia and acute kidney injury, NGAL is one of the earliest substances
83 that are released into the urine. However, there are limited studies of NGAL in SCD as a marker of
84 renal tubular damage and SCN(10).In cancer studies, the fibrinogen-to-albumin ratio (FAR) was a
85 more significant predictive factor than each indicator itself (11). The purpose of this study is to see
86 if NGAL and FAR could be used as indicators of renal impairment in sickle cell disease patients.

87 **Materials and Methods**

88 **Study design, duration and study setting**

89 The present study utilized a prospective case-control design and it was conducted at Komfo Anokye
90 Teaching Hospital (KATH), Kumasi South Government Hospital and Suntreso Government
91 Hospital from November 25, 2023 to March 31, 2024. The KATH is located at Bantama, Kumasi,
92 Ashanti Region, Ghana. It is the sole tertiary healthcare facility in the Ashanti Region and the
93 second-largest hospital in Ghana. Kumasi South Hospital is located in Atonsu Agogo and Suntreso

94 Government Hospital is located in Suntreso. These facilities are situated in the Kumasi Metropolis
95 in the Ashanti Region of Ghana. They are a 24- hour working health facilities that boast of services
96 like laboratory, radiology, obstetrics and gynaecology, surgery, paediatrics, internal medicine and
97 emergency among others. They also have a sickle cell clinic from where SCD participants were
98 recruited for the study.

99 **Ethical Clearance and Informed Consent**

100 The Komfo Anokye Teaching Hospital's (KATH IRB/AP/175/23) and Kwame Nkrumah University
101 of Science and Technology's (CHRPE/AP/1037/23) committees on human research and publication
102 ethics approved the study. Once the study participants had received a thorough explanation of the
103 study's objectives, advantages, risks, and right to withdraw at any time in both English and the local
104 dialect (primarily Twi), their written consent was requested.

105 **Study population and selection of participants**

106 According to this study, the participants classified as cases comprised individuals who have been
107 medically diagnosed with SCD. The cases were further categorized into sickle cell nephropathy and
108 sickle cell non-nephropathy subjects based on reduced estimated Glomerular Filtration Rate (eGFR)
109 and microalbuminuria. The individuals classified as controls on the other hand, were characterized
110 by their overall good health and absence of sickle cell disease and nephropathy.

111 The aim of the study was explained to the study participants. Then, the processes involved in the
112 study, including blood and urine sampling, data collection and laboratory assays were explained
113 to the eligible participants with the help of a clinician.

114 We then purposively recruited a total of 104 SCD patients and 80 healthy individuals, of which 51
115 healthy individuals were without nephropathy and were analysed. The SCD patients were registered
116 with the sickle cell clinic at the Komfo Anokye Teaching Hospital and Kumasi South Government

117 Hospital. They reported at the clinic for a review as and when directed by their physician. Owing to
118 their clinical history, physicians in both hospitals assessed the SCD patients and declared them fit
119 for the study before they were recruited. Healthy controls were blood donors from the blood bank
120 units of Suntreso Government hospital and Komfo Anokye Teaching Hospital.

121 SCD patients who are above eighteen (18) years in a steady state for at least one month, and are
122 without history of diabetes mellitus, arterial hypertension, neoplastic, cardiovascular, renal, lung or
123 endocrine disease were eligible for this study. Also, SCD participants who had symptoms suggestive
124 of sickle cell pain crisis, acute sickness (fever or required referral to an urgent care facility),
125 clinically suspected urinary tract infection and extensive haematuria were excluded. Healthy
126 individuals without history of SCD, diabetes mellitus, arterial hypertension, neoplastic,
127 cardiovascular, inflammatory, renal, lung and endocrine diseases were also eligible for the control
128 group.

129 **Data collection**

130 Important demographic and clinical history information about the participants were recorded using
131 a well-structured questionnaire and patient case records. Animal protein consumption (fish, meat
132 & egg) were categorised qualitatively as occurring rarely (one per month), irregularly (seven times
133 per month), and regularly (twice per month). A wall-mounted ruler was used to measure height. A
134 Zhongshan Camry Electronic Co. Ltd. bathroom scale (Guangdong, China) was used to assess
135 weight. Estimates were made for height to the nearest centimetre without shoes and weight to the
136 nearest 0.1 kg when wearing light clothes.

137 **Sampling and analysis**

138 Blood samples were collected following standard protocol (World Health Organization, 2010). Five
139 (5) millilitres (ml) (venous blood) were pulled from each participant and collected into K3 EDTA

140 tube, sodium citrate tube and Serum Separator tube (SST) – 1.8ml into sodium citrate tube first, 2.2
141 ml separated into SST second and 1ml into 4ml EDTA tube. Whole blood in EDTA was used for
142 Haemogram analysis. Serum in SST was used to analyze liver function markers, creatinine, urea,
143 electrolytes (sodium, potassium and chloride) and NGAL. Sodium citrate was used for fibrinogen
144 measurement. Participants were directed to collect a mid-stream urine in a cleaned dry urine
145 container. Mid-stream urine sample was used for UACR.

146 **Laboratory assays**

147 Participants' haemoglobin variants were confirmed by Hb electrophoresis. Full Blood Estimation
148 was done using five (5)- part Automated Haematology Analyser XN-550 (XN-550; Sysmex
149 Corporation, Kobe Japan). Kidney function tests (electrolytes, urea, and creatinine), liver function
150 tests (bilirubin, AST,ALT, ALP, GGT Total Protein and albumin), urine albumin-to-creatinine ratio
151 were determined on Vitros 5600 integrated systems. Estimated GFR (eGFR) was calculated using
152 the Chronic Kidney Disease Epidemiology Collaboration creatinine equation (2009) (eGFR_{creat}).
153 Normoalbuminuria and microalbuminuria were defined as urine microalbumin:creatinine ratio < 30
154 mg/g and ≥ 30mg/g respectively. Fibrinogen was measured with Wonfo Fibrinogen reagent kit and
155 OCG-102 Coagulation analyzer. Fibrinogen-to-Albumin ratio calculations involved dividing the
156 Fibrinogen (FIB) by serum Albumin (ALB) to arrive at values. A commercially available ELISA
157 kit (Melson Shanghai Chemical Ltd, China) was used for the sNGAL measurement. Reagent was
158 used in accordance with the manufacturer's instructions to measure samples from the controls and
159 the participants using the solid phase ELISA technique. The commonly accepted reference value
160 for serum NGAL is 5.68±1.34µg/L.

161

162 **Determination of sickle cell nephropathy**

163 The 2024 KDIGO classification (12) for establishing chronic kidney disease guidelines was used.
164 Reduced eGFR and microalbuminuria were the main determinants of sickle cell nephropathy. For
165 eGFR, nephropathy was classified as individual with reduced eGFR ($<60\text{mL}/\text{min}/1.73\text{m}^2$) and
166 without nephropathy ($\geq 60\text{mL}/\text{min}/1.73\text{m}^2$). Estimated GFR (eGFR) was calculated using the
167 Chronic Kidney Disease Epidemiology Collaboration creatinine equation (2009) (eGFR_{creat}) (13).
168 Microalbuminuria was determined by urine albumin-to-creatinine ratio (UACR) greater than or
169 equal to $30\text{mg}/\text{g}$ and normoalbuminuria was defined as UACR less than $30\text{ mg}/\text{g}$.

170 **Statistical analysis**

171 The study's data were entered and cleaned in Microsoft Excel (2016). The data were exported to R
172 programming version 4.2.3, and IBM Statistical Package for Social Sciences (version 26.0) for
173 analysis. Continuous variables were expressed as mean \pm standard deviation or median interquartile
174 ranges depending on the normality while categorical variables were expressed as frequency and
175 percentages. The association of participants baseline parameters between the study groups was
176 investigated using the chi-square test. In addition, the post-hoc Bonferroni test and one-way
177 ANOVA or Kruskal Wallis test followed by pairwise multiple comparisons were used to evaluate
178 the variations in continuous variable between study groups, depending on the normality. To examine
179 the relationship between sNGAL, eGFR, FAR, and UACR, Spearman's correlation was employed
180 and results represented as heatmaps. Using the Receiver Operator Characteristics Curve, the area
181 under the curves for sNGAL, Urea, Creatinine and FAR for predicting sickle cell nephropathy were
182 determined. All computations of statistical significance were performed using a 95% confidence
183 interval and a *p-value* of 0.05.

184 **Results**

185 **Baseline characteristics of study participants**

186 A total of 104 patients (46 males and 58 females) with SCD were recruited. Seventy four (74) were
187 HbSS and thirty were (30) were HbSC. They were all in steady state based on their clinical status
188 assessed by haematologists. Fifty one (51) healthy individuals (13 males and 38 females) were
189 analysed. Following the 2024 KDIGO classification (12) for establishing chronic kidney disease
190 guidelines, 34(32.7%) out of the 104 SCD patients had microalbuminuria. Subsequently, eleven (11)
191 out of the thirty-four (34) SCD participants with microalbuminuria ($UACR \geq 30$) had reduced eGFR
192 ($< 60 \text{ mL/min/1.73m}^2$), because microalbuminuria is the superior sensitive marker for kidney damage
193 as indicated in the KDIGO guidelines, 34(32.7%) of SCD participants were diagnosed with
194 nephropathy while 70(67.3%) were without nephropathy. Gender varied significantly across the
195 groups ($p=0.017$) with 96(61.9%) being females and males being 59(38.1%). Again, the distribution
196 of age across the cases and controls was statistically significant ($p=0.013$) as majority of them were
197 less than 25 years 84(54.2%) and were more in the SCD non-nephropathy group 42(50.0%). The
198 participants' BMI varied significantly among the cases and controls ($p<0.0001$) as majority were
199 having normal weights with least being obese 2(1.3%). Nearly all 152(98.1%) rarely smoked
200 tobacco and the difference across the groups was significant ($p=0.044$) and were rarely 139(89.7%)
201 taking in alcohol ($p=0.004$). Although, there were no significant relation ($p>0.05$) across the groups
202 but larger proportion of the participants irregularly exercise 101(62.2%), and take in salt 97(62.6%),
203 regularly consume meat & fish 122(78.7%), and egg 126(81.3%) (**Table 1**).

204 **Haemato-biochemical Profile of SCD nephropathy, SCD non-nephropathy and controls**

205 Both diastolic and systolic blood pressures differed significantly across groups. Creatinine was
206 elevated in the SCD nephropathy group ($p=0.0320$), compared to SCD non-nephropathy group.

207 Electrolyte levels such as sodium and potassium were significantly different across groups, with
208 controls showing lower levels of sodium and potassium ($p<0.0001$ and $p=0.0020$, respectively).
209 AST, ALP, and total bilirubin were also significantly different across groups ($p<0.0001$). Moreover,
210 hematological indices including RBC count, hematocrit, and hemoglobin were significantly lower
211 in the SCD nephropathy group ($p<0.0001$), whilst inflammatory markers like WBC, neutrophil
212 count, and monocyte count were higher ($p<0.0001$). Serum NGAL and eGFR levels also showed
213 significant differences, with SCD nephropathy patients having the highest sNGAL ($p<0.0001$) and
214 the lowest eGFR ($p=0.0250$) (**Table 2**).

215 **Correlation between sNGAL and biochemical parameters**

216 There was a significant positive correlation between sNGAL and UACR, a significant negative
217 correlation between UACR and eGFR. There was a weak but significant correlation between
218 potassium and sNGAL ($r=0.29$, $p<0.005$), a significant moderate negative correlation between eGFR
219 and urea ($r=-0.50$, $p<0.0005$) and a strong negative correlation with creatinine as it is already
220 established ($r=-0.90$, $p<0.0005$). UACR also correlated weakly but significantly with creatinine in
221 a direct proportion ($r=0.27$, $p<0.005$) (**Figure 1**).

222 **Diagnostics performance of sNGAL, Creatinine, Urea and FAR in predicting nephropathy** 223 **among SCD patients**

224 Using the Receiver Operating Curve (ROC) analysis for predicting nephropathy among SCD
225 patients, sNGAL as a marker at a cutoff of >5.72 significantly predicted nephropathy among SCD
226 patients with high Area under the Curve ($AUC=0.742$, $p<0.0001$) and was very sensitive (91.2%)
227 but less specific (51.4%). Also, Creatinine at a cutoff of >96.0 marginally predicted nephropathy
228 among SCD patients significantly with $AUC=0.618$, $p=0.048$ however, it was less sensitive (47.1%)

229 but specific (81.4%). Urea and FAR predicted with an AUC=0.531 and AUC=0.462 respectively but
230 were not statistically significant ($p>0.05$) (Table 3 and Figure 2).

231 Discussion

232 Renal involvement in SCD is demonstrated by the presence of crescent RBCs in the renal medulla,
233 which cause ischemia, microinfarcts, reduced renal medullary blood flow, and renal papillary
234 necrosis (14). Conventional renal markers remain normal until extensive renal damage hence the
235 necessity for early diagnostic markers allows for implementation of preventive actions (15). This
236 case-control study assessed NGAL and FAR as indicators for nephropathy among non-hospitalized
237 SCD patients who were unaware of their renal status.

238 Most of the SCD patients were individuals with HbSS variant followed by HbSC variant which
239 agrees with a research mastered by Ohene Frimpong *et al.*, (2008) and Ephraim *et al.*, (2015) from
240 Ghana (16). Ko *et al.*, (2017) (17) reported that high protein intake can cause injury to the glomerular
241 structure resulting in CKD which favors the high protein intake association with nephropathy in
242 SCD subjects. However, restriction of protein intake is not recommended mainly due to the low
243 energy state of SCD patients especially those with HbSS which may also explain the high protein
244 intake in sickle cell nephropathy.

245 Prevalence of nephropathy among adult steady state SCD participants was 32.7% as indicated in
246 2024 KDIGO classification(12). This is above a prevalence of 17.1% nephropathy based on
247 microalbuminuria found by Marouf *et al.*, (2021) in Kuwait. However, this is below the prevalence
248 indicated in a study by Ephraim *et al.*, (2015) that found that 68.4% of adult SCD patients had CKD
249 based on reduced eGFR in Ghana. The variation in the prevalences might be due to the fact that
250 eGFR only explore the function of the kidney whilst microalbuminuria determines kidney damage
251 as indicated in KDIGO classification.

252 With respect to FBC parameters, there was lower haemoglobin and RBC levels in SCD
253 nephropathy (SCN) participants compared to controls and SCD non-nephropathy (Non-SCN)
254 participants. This confirms the significant association between haemoglobin, RBC and
255 hematocrit levels and kidney disease as already indicated by various studies(18-22). We also
256 reported significant difference between SCN, Non-SCN and healthy individuals with respect to
257 total WBC levels and differentials in a decreasing order which tells the story that SCD is an
258 inflammatory disease and get worse when there is an additional inflammatory disorder like
259 nephropathy which agrees with several studies (5, 23, 24). Also, in a prospective study
260 conducted by Aneke *et al.*, (2014) in Nigeria reported high levels of platelets in SCD
261 participants with CKD which is in agreement with this present study (25). The pattern of WBC
262 and platelets levels among participants justify the increase in inflammation in the SCN group
263 resulting in high levels of NGAL, FAR and renal parameters. With respect to LFT parameters,
264 ALT which is very specific to liver was apparently normal and similar in participant groups
265 which rules out liver dysfunction in study participants. LFT markers seen in this study is in
266 accordance with a research done by Kotila *et al.*, (2005) who observed minimal elevation of
267 transaminases in steady state SCD patients (26). As far as the kidney biomarkers are concern,
268 this study reported markely increased levels of creatinine and urea which conforms to a research
269 done by Ephraim *et al.*, (2015) in Ghana. There was a minimal increased levels of potassium in
270 the SCN compared to the controls which agrees with findings from Alhwiesh *et al.*, (2015).
271 NGAL was significantly higher in the SCN group as compared to the healthy controls. Marouf *et*
272 *al.*, (2020) and Atere *et al.*, (2018) found increased levels of NGAL in steady state SCD pateints
273 and its relationship with renal abnormailities as comapred to healthy individuals which is
274 consistent with this present study. Fibrinogen-to-albumin ratio was significantly higher in the SCN

275 as compared to Non-SCN and healthy controls(27). Increased fibrinogen and hypoalbuminuria
276 are biomarkers of inflammation, this was evident by a study conducted by Luyendyk *et al.*, (2019)
277 and Zhang *et al.*, (2019), who also found their correlation with renal prognosis which agree with
278 this study. This study found a significant positive correlation between NGAL and UACR which is
279 in line with a study performed by Marouf *et al.*, (2021) who found a positive non-significant
280 correlation between plasma NGAL and UACR but a positive significant correlation between urine
281 NGAL and UACR. This observation could be attributed to the state of patients in that they
282 recruited both steady and VOC SCD and they were not grouped in the correlation analysis. There
283 was also a negative statistically significant correlation between eGFR and UACR. Also, there was
284 a significant strong negative correlation between eGFR and a mild significant negative relationship
285 existed between urea and eGFR. These observations are comparable to findings from (4, 5, 15, 28,
286 29). The optimal threshold at which NGAL level indicated impairment of the of kidney was
287 5.72ug/l with a sensitivity of 91.2% and specificity of 51.4%. Comparing the Area under the
288 curves NGAL significantly performed better than the conventional markers (urea and creatinine)
289 with higher sensitivity (91.2%) than creatinine (47.1%) and that of urea (41.2%). However,
290 creatinine was highly specific but the AUC value was lower than that of NGAL, unlike urea that
291 had non-significant specificity and lower AUC value. This tells an interesting story that once there
292 is kidney impairment in SCD individuals in steady state, NGAL would be able to detect it and can
293 be used as a predictive marker for nephropathy. These observations are comparable to a research
294 conducted by Atere *et al.*, (2018) in Nigeria who compared the AUC of NGAL and conventional
295 markers (Urea and Creatinine) with NGAL having a superior AUC than urea and creatinine in both
296 steady and VOC states. However, Marouf and associates indicated that urine NGAL performs
297 better than plasma NGAL in predicting nephropathy in SCD in VOC state but could not find that

298 of SCD in steady state. Various studies have also compared NGAL levels in other non-SCD
299 nephropathy studies indicating that NGAL was a better marker for nephropathy even in non-SCD
300 patients which should be well looked at (29-32). Fibrinogen-to-albumin ratio performed poorly in
301 the ROC analysis with a non-significant low sensitivity and specificity which indicates that FAR
302 levels could not be used to predict nephropathy in SCD subjects as seen in a cancer study by
303 Hwang *et al.*, (2017) which is inconsistent with this study, though FAR could be used to track
304 nephropathy treatment due to the higher levels in SCD nephropathy group in this study.

305 Despite the novel findings, this study had limitations worth mentioning. The study recruited only
306 steady state SCD patients and thus not entirely a true reflection of all SCD adult patients. Also,
307 most of the SCD participants were young adults and may not be a reflective of old SCD patients.

308 Further studies should recruit both steady state and VOC state adult SCD patients with equal age
309 distribution. Urine albumin-to-creatinine ratio should be added to estimated glomerular filtration
310 rate as suggested by KDIGO to confirm chronic kidney disease and thus classify sickle cell
311 nephropathy. Further studies should be done to assess relationship between serum NGAL and
312 urine NGAL and how they predict sickle cell nephropathy.

313 **Conclusion**

314 In conclusion, this is the first attempt to investigate NGAL and FAR as indicators of
315 nephropathy among adult steady state SCD patients in Ghana. The study demonstrated a
316 higher NGAL and FAR levels among SCD with nephropathy as compared to apparently
317 healthy individuals. The study demonstrated a significant correlation between Neutrophil
318 Gelatinase- Associated Lipocalin and Albumin-to-Creatinine Ratio (UACR). Finally,
319 NGAL as independent marker, is an early predictor of kidney disease as compared to urea
320 and creatinine. Fibrinogen-to-albumin ratio can be used to track nephropathy treatment in

321 steady state sickle cell disease patients since it is elevated in those with sickle cell
322 nephropathy compared to healthy individuals.

323 **Acknowledgements**

324 We are grateful for the immense contributions of the staff of Komfo Anokye Teaching Hospital,
325 Suntreso Government Hospital and Kumasi South Hospital for their warm reception, not forgetting
326 our participants. Special thanks to the serology department of Komfo Anokye Teaching Hospital
327 on their support in storage of samples.

328 **Authors' contributions**

329 **Conceptualization:** Stephen Twumasi, Lilian Antwi Boateng, Enoch Odame Anto, Benedict
330 Sackey, Allwell Adofo Ayirebi

331 **Data curation:** Stephen Twumasi, Lesle Osei, Angela Opoku

332 **Formal analysis:** Stephen Twumasi, Richard Owusu Ansah, Godfred Yawson Scott, Alfred Effah

333 **Investigation:** Stephen Twumasi, Lilian Antwi Boateng, Enoch Odame Anto, Angela Opoku,
334 Leslie Osei, Vivian Paintsil, Joyce Duku, Emmanuel Asafo Adjei

335 **Methodology :** Stephen Twumasi, Lilian Antwi Boateng, Enoch Odame Anto

336 **Project administration:** Stephen Twumasi, Lilian Antwi Boateng, Enoch Odame Anto

337 **Resources:** Stephen Twumasi, Angela Opoku

338 **Software:** Stephen Twumasi, Richard Owusu Ansah, Godfred Yawson Scott, Alfred Effah

339 **Supervision:** Stephen Twumasi, Lilian Antwi Boateng, Christian Obirikorang, Enoch Odame
340 Anto

341 **Validation:** Stephen Twumasi, Lilian Antwi Boateng & Enoch Odame Anto

342 **Visualization:** Stephen Twumasi, Lilian Antwi Boateng & Enoch Odame Anto

343 **Writing-original drtaft:** Stephen Twumasi, Lilian Antwi Boateng, Enoch Odame Anto, Richard
344 Kobina Dadzie Ephraim, Christian Obirikorang, Benedict Sackey, Allwell Adofo Ayerebi

345 **Writing-review & editing:** Stephen Twumasi, Enoch Odame Anto, Benedict Sackey, Christian
346 Obirikorang, Alfred Effah, Richard Kobina Dadzie Ephraim, Allwell Adofo Ayirebi, Godfred
347 Yawson Scott, Richard Owusu Ansah, Angela Opoku, Leslie Osei, Vivian Paintsil, Joyce Duku,
348 Emmanuel Asafo Adjei, Lilian Antwi Boateng

349 **Funding**

350 The author(s) received no financial support for the research, authorship and or/ publication of this
351 article.

352 **Availability of data**

353 Data and materials for study are available upon request from the corresponding authors.

354 **Declarations**

355 The study was approved by the Committee on Human Research and Publication Ethics of the
356 Kwame Nkrumah University of Science and Technology (CHRPE/AP/1037/23) and Komfo
357 Anokye Teaching Hospital (KATH IRB/AP/175/23). Written consent of individual participants
358 was sought after the aims, benefits, risk and right of withdrawal at any time from the study were
359 well explained to the study participants in English and in the local dialect (mostly Twi) and their
360 consent was obtained.

361 **Consent for publication**

362 Not applicable.

363 **Competing interests**

364 All authors declare that there is no competing interest.

365 REFERENCES

- 366 1. Voskaridou E, Terpos E, Michail S, Hantzi E, Anagnostopoulos A, Margeli A, et al.
367 Early markers of renal dysfunction in patients with sickle cell/ β -thalassemia. *Kidney*
368 *international*. 2006;69(11):2037-42.
- 369 2. Saborio P, Scheinman JI. Sickle cell nephropathy. *Journal of the American Society of*
370 *Nephrology*. 1999;10(1):187-92.
- 371 3. Gurkan S, Scarponi KJ, Hotchkiss H, Savage B, Drachtman R. Lactate dehydrogenase as
372 a predictor of kidney involvement in patients with sickle cell anemia. *Pediatric nephrology*.
373 2010;25:2123-7.
- 374 4. Anto EO, Obirikorang C, Acheampong E, Adua E, Donkor S, Afranie BO, et al. Renal
375 abnormalities among children with sickle cell conditions in highly resource-limited setting in
376 Ghana. *PloS one*. 2019;14(11):e0225310.
- 377 5. Ephraim RKD, Osakunor DNM, Cudjoe O, Oduro EA, Asante-Asamani L, Mitchell J, et
378 al. Chronic kidney disease is common in sickle cell disease: a cross-sectional study in the Tema
379 Metropolis, Ghana. *BMC nephrology*. 2015;16:1-7.
- 380 6. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, et al. A more accurate
381 method to estimate glomerular filtration rate from serum creatinine: a new prediction equation.
382 *Annals of internal medicine*. 1999;130(6):461-70.
- 383 7. Aygun B, Mortier NA, Smeltzer MP, Hankins JS, Ware RE. Glomerular hyperfiltration
384 and albuminuria in children with sickle cell anemia. *Pediatric nephrology*. 2011;26:1285-90.
- 385 8. Sundaram N, Bennett M, Wilhelm J, Kim MO, Atweh G, Devarajan P, et al. Biomarkers
386 for early detection of sickle nephropathy. *American journal of hematology*. 2011;86(7):559-66.
- 387 9. Sise ME, Barasch J, Devarajan P, Nickolas TL. Elevated urine neutrophil gelatinase-
388 associated lipocalin can diagnose acute kidney injury in patients with chronic kidney diseases.
389 *Kidney international*. 2009;75(1):115-6.
- 390 10. Audard V, Moutereau S, Vandemelebrouck G, Habibi A, Khellaf M, Grimbert P, et al.
391 First evidence of subclinical renal tubular injury during sickle-cell crisis. *Orphanet Journal of*
392 *Rare Diseases*. 2014;9:1-4.
- 393 11. Hwang K-T, Chung JK, Roh EY, Kim J, Oh S, Kim YA, et al. Prognostic influence of
394 preoperative fibrinogen to albumin ratio for breast cancer. *Journal of breast cancer*.
395 2017;20(3):254-63.
- 396 12. KDIGO-CKD. WG. KDIGO 2024 Clinical Practice Guideline for the Evaluation and
397 Management of Chronic Kidney Disease. *Kidney Int* 2024;105(4S): S117–S314.
- 398 13. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A
399 new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009;150(9):604-12.
- 400 14. Alhwiesh A. An update on sickle cell nephropathy. *Saudi Journal of Kidney Diseases and*
401 *Transplantation*. 2014;25(2):249-65.
- 402 15. Marouf R, Adekile AD, El-Muzaini H, Abdulla R, Mojiminiyi OA. Neutrophil
403 gelatinase-associated lipocalin as a biomarker of nephropathy in sickle cell disease. *Annals of*
404 *Hematology*. 2021;100:1401-9.
- 405 16. Ohene-Frempong K, Oduro J, Tetteh H, Nkrumah F. Screening newborns for sickle cell
406 disease in Ghana. *Pediatrics*. 2008;121(Supplement_2):S120-S1.
- 407 17. Ko GJ, Obi Y, Tortorici AR, Kalantar-Zadeh K. Dietary protein intake and chronic
408 kidney disease. *Current Opinion in Clinical Nutrition & Metabolic Care*. 2017;20(1):77-85.

- 409 18. de Francisco AL, Stenvinkel P, Vaulont S. Inflammation and its impact on anaemia in
410 chronic kidney disease: from haemoglobin variability to hyporesponsiveness. *NDT plus*.
411 2009;2(suppl_1):i18-i26.
- 412 19. Drüeke TB, Locatelli F, Clyne N, Eckardt K-U, Macdougall IC, Tsakiris D, et al.
413 Normalization of hemoglobin level in patients with chronic kidney disease and anemia. *New*
414 *England Journal of Medicine*. 2006;355(20):2071-84.
- 415 20. Duncan JA, Levin A. Sex, haemoglobin and kidney disease: new perspectives. *European*
416 *journal of clinical investigation*. 2005;35:52-7.
- 417 21. Saraf SL, Zhang X, Kaniyas T, Lash JP, Molokie RE, Oza B, et al. Haemoglobinuria is
418 associated with chronic kidney disease and its progression in patients with sickle cell anaemia.
419 *British journal of haematology*. 2014;164(5):729-39.
- 420 22. Strippoli GF, Navaneethan SD, Craig JC, Palmer SC. Haemoglobin and haematocrit
421 targets for the anaemia of chronic kidney disease. *Cochrane Database of Systematic Reviews*.
422 2006(4).
- 423 23. Drawz P, Ayyappan S, Nouraie M, Saraf S, Gordeuk V, Hostetter T, et al. Kidney disease
424 among patients with sickle cell disease, hemoglobin SS and SC. *Clinical Journal of the American*
425 *Society of Nephrology*. 2016;11(2):207-15.
- 426 24. Okpala I. The intriguing contribution of white blood cells to sickle cell disease—a red cell
427 disorder. *Blood reviews*. 2004;18(1):65-73.
- 428 25. Aneke JC, Adegoke A, Oyekunle A, Osho P, Sanusi A, Okocha E, et al. Haematological
429 and clinical profile in Nigerian sickle cell disease patients with and without chronic kidney
430 disease. *Orient Journal of Medicine*. 2014;26(3-4):88-93.
- 431 26. Kotila T, Adedapo K, Adedapo A, Oluwasola O, Fakunle E, Brown B. Liver dysfunction
432 in steady state sickle cell disease. *Annals of hepatology*. 2005;4(4):261-3.
- 433 27. Hariri E, Mansour A, El Alam A, Daaboul Y, Korjian S, Aoun Bahous S. Sickle cell
434 nephropathy: an update on pathophysiology, diagnosis, and treatment. *International Urology and*
435 *Nephrology*. 2018;50:1075-83.
- 436 28. Atere A, Ajani O, Akinbo D, Adeosun O, Anombem O. Serum levels of neutrophil
437 gelatinase-associated lipocalin (NGAL) as predictor of acute kidney injury in sickle cell subjects.
438 *J Biomed Sci*. 2018;7(4):17.
- 439 29. Danquah M, Owiredu WK, Jnr BE, Serwaa D, Odame Anto E, Peprah MO, et al.
440 Diagnostic value of neutrophil gelatinase-associated lipocalin (NGAL) as an early biomarker for
441 detection of renal failure in hypertensives: a case–control study in a regional hospital in Ghana.
442 *BMC nephrology*. 2023;24(1):114.
- 443 30. Bolignano D, Donato V, Coppolino G, Campo S, Buemi A, Lacquaniti A, et al.
444 Neutrophil gelatinase–associated lipocalin (NGAL) as a marker of kidney damage. *American*
445 *journal of kidney diseases*. 2008;52(3):595-605.
- 446 31. Liu H, Wan X, Shi Y, Huang F, Shu H, Huang R, et al. Neutrophil gelatinase-associated
447 lipocalin contributes to increased risk of cardiovascular death after acute coronary syndrome.
448 *International Journal of General Medicine*. 2021:4887-95.
- 449 32. Prashant P, Dahiya K, Bansal A, Vashist S, Dokwal S, Prakash G. Neutrophil Gelatinase-
450 Associated Lipocalin (NGAL) as a potential early biomarker for diabetic nephropathy: a meta-
451 analysis. *International Journal of Biochemistry and Molecular Biology*. 2024;15(1):1.

452

453

454 **Table 1: Baseline characteristics of study participants**

Variables	Total N=155	Control n=51	Cases=104(67.1%)		p-value
			SCD non- nephropathy n=70	SCD Nephropathy n=34	
Age Group (years)					0.013
<25	84(54.2)	18(31.4)	42(50.0)	24(28.6)	
25-34	38(24.5)	14(36.8)	16(42.1)	8(21.1)	
35-44	19(12.3)	11(57.9)	7(36.8)	1(5.3)	
>44	14(9.0)	8(57.1)	5(35.7)	1(7.1)	
Gender					0.017
Male	59(38.1)	13(22.0)	35(59.3)	11(18.6)	
Female	96(61.9)	38(39.6)	35(36.5)	23(24.0)	
BMI					<0.0001
Underweight	9(5.8)	0(0.0)	4(44.4)	5(55.6)	
Normal	101(65.2)	23(22.8)	55(54.5)	23(22.8)	
Overweight	43(27.7)	28(65.1)	9(20.9)	6(14.0)	
Obese	2(1.3)	0(0.0)	2(100.0)	0(0.0)	
SCD Phenotype					0.819*
HbSC	30(28.8)	-	21(70.0)	9(30.0)	
HbSS	74(71.2)	-	49(66.2)	25(33.8)	
Vigorous Exercise					0.784
Regular	46(29.7)	16(34.8)	22(47.8)	8(17.4)	
Irregular	101(65.2)	33(32.7)	45(44.6)	23(22.8)	
Rarely	8(5.2)	2(25.0)	3(37.5)	3(37.5)	
Meat&Fish Consumption					0.508
Regular	122(78.7)	38(31.1)	59(48.4)	25(20.5)	
Irregular	31(20.0)	12(38.7)	10(32.3)	9(29.0)	
Rarely	2(1.3)	1(50.0)	1(50.0)	0(0.0)	
Egg Consumption					0.056
Regular	126(81.3)	36(28.6)	61(48.4)	29(23.0)	
Irregular	29(18.7)	15(51.7)	9(31.0)	5(17.2)	
Tobacco Smoking					0.044
Irregular	3(1.9)	3(100.0)	0(0.0)	0(0.0)	
Rarely	152(98.1)	48(31.6)	70(46.1)	34(22.4)	
Alcohol Intake					0.004
Regular	2(1.3)	2(100.0)	0(0.0)	0(0.0)	
Irregular	14(9.0)	10(71.4)	2(14.3)	2(14.3)	
Rarely	139(89.7)	39(28.1)	68(48.9)	32(23.0)	

Salt Intake					0.066
Regular	47(30.3)	14(29.8)	21(44.7)	12(25.5)	
Irregular	97(62.6)	29(29.9)	47(48.5)	21(21.6)	
Rarely	11(7.1)	8(72.7%)	2(18.2)	1(9.1)	

455 BMI: Body Mass Index, HbSS; Haemoglobin SS, HbSC; Haemoglobin SC, Data presented as frequency (%). Chi-
456 square *p*-values were presented, *p*<0.05 was considered statistically significant. Bolded *p*-value was statistically
457 significant, * ; Fisher Exact test computed for the cases only

458

Table 2: Haemato-biochemical Profile of SCD patients nephropathy, SCD non-nephropathy and controls

Variable	SCD non-nephropathy (n = 70)	SCD Nephropathy n = (34)	Controls (n = 51)	p-value
Diastolic Blood Pressure (mm Hg)	71.00 (67.00 - 76.00)	71.50 (64.75 - 76.50)	76.00 (74.00 - 79.00)	< 0.0001 ^{b,c}
Systolic Blood Pressure (mm Hg)	119.00 (112.00 - 121.25)	119.00 (112.00 - 127.00)	112.00 (109.00 - 119.00)	< 0.0001 ^{b,c}
Urea (mmol/L)	2.10 (1.58 - 2.87)	2.19 (1.31 - 5.05)	2.60 (1.63 - 3.03)	0.7890
Creatinine (mmol/L)	53.50 (44.00 - 76.25)	72.00 (47.00 - 156.00)	68.00 (52.00 - 77.00)	0.0320 ^a
BUN/Creatinine ratio	18.15 (13.48 - 24.90)	17.35 (13.55 - 23.05)	16.40 (12.50 - 21.10)	0.2300
Sodium (mmol/L)	142.00 (141.00 - 144.00)	143.00 (140.75 - 145.00)	140.00 (139.00 - 142.00)	< 0.0001 ^{b,c}
Potassium (mmol/L)	4.60 (4.50 - 5.00)	4.90 (4.60 - 5.20)	4.40 (4.00 - 4.80)	0.0020 ^c
Chlorine (mmol/L)	106.00 (102.00 - 109.00)	107.00 (102.00 - 110.00)	104.00 (103.00 - 107.00)	0.2780
Aspartate Transaminase (U/L)	47.55 (37.38 - 59.13)	50.75 (38.90 - 70.25)	32.00 (28.40 - 38.90)	< 0.0001 ^{b,c}
Alanine Transaminase (U/L)	23.90 (20.83 - 32.35)	25.20 (19.65 - 28.65)	24.80 (17.60 - 31.40)	0.8070
Alkaline Phosphatase (U/L)	103.05 (77.83 - 135.55)	99.20 (71.63 - 166.33)	72.10 (59.40 - 94.30)	< 0.0001 ^{b,c}
GGT (U/L)	41.50 (24.88 - 56.53)	36.15 (24.55 - 53.25)	26.80 (22.70 - 40.50)	0.0140 ^b
Albumin (g/L)	41.80 (39.88 - 43.80)	41.60 (38.55 - 44.05)	42.20 (39.30 - 44.60)	0.4500
Total Bilirubin (mmol/L)	27.00 (15.78 - 38.88)	29.55 (15.38 - 41.65)	6.10 (4.10 - 11.30)	< 0.0001 ^{b,c}
Direct Bilirubin (mmol/L)	1.40 (0.00 - 5.10)	2.65 (0.00 - 5.90)	1.80 (0.90 - 3.00)	0.4970
Indirect Bilirubin (mmol/L)	24.25 (13.50 - 35.05)	24.25 (13.93 - 39.33)	4.10 (3.10 - 8.10)	< 0.0001 ^{b,c}
Fibrinogen (g/L)	4.31 (3.39 - 5.17)	4.35 (2.71 - 5.12)	2.40 (2.01 - 3.24)	< 0.0001 ^{b,c}
FAR	0.10 (0.08 - 0.12)	0.11 (0.07 - 0.12)	0.06 (0.05 - 0.08)	< 0.0001 ^{b,c}
RBC (10 ⁶ /mL)	3.08 (2.52 - 3.94)	2.73 (2.43 - 3.47)	4.42 (3.96 - 4.85)	< 0.0001 ^{b,c}
Hematocrit (%)	25.75 (22.90 - 29.68)	24.50 (21.75 - 30.13)	35.60 (31.90 - 39.50)	< 0.0001 ^{b,c}
MCV (fL)	85.80 (74.75 - 96.50)	88.30 (78.00 - 94.78)	81.40 (76.40 - 85.10)	0.0170 ^{b,c}
MCH (pg)	29.55 (25.98 - 32.78)	30.30 (27.25 - 32.85)	27.70 (25.00 - 29.20)	0.0020 ^{b,c}
MCHC (g/dL)	35.35 (32.75 - 36.60)	34.70 (32.85 - 36.03)	33.90 (32.60 - 34.70)	0.0060 ^b
RDW-SD (fL)	59.00 (46.85 - 66.30)	61.90 (50.98 - 71.53)	40.10 (38.20 - 42.80)	< 0.0001 ^{b,c}
RDW-CV (%)	19.20 (17.08 - 22.73)	19.80 (17.50 - 25.35)	13.80 (12.90 - 14.60)	< 0.0001 ^{b,c}
PLT (10 ³ /mL)	279.00 (171.75 - 375.50)	325.00 (214.25 - 455.25)	248.00 (205.00 - 292.00)	0.0490 ^c
PDW (fL)	11.80 (9.90 - 13.50)	12.45 (10.48 - 14.73)	12.40 (11.40 - 13.70)	0.2510
MPV (fL)	10.50 (9.48 - 11.50)	11.00 (10.00 - 11.98)	10.90 (10.40 - 11.40)	0.1860
PCT (%)	0.30 (0.20 - 0.40)	0.36 (0.23 - 0.51)	0.27 (0.24 - 0.33)	0.0550

WBC (10 ³ /mL)	8.38 (6.03 - 10.97)	8.91 (7.70 - 9.85)	5.57 (4.90 - 6.85)	<0.0001^{b,c}
Lymphocyte Count (10 ³ /mL)	3.37 (2.47 - 4.21)	3.44 (2.89 - 3.89)	2.18 (1.87 - 2.63)	<0.0001^{b,c}
Monocyte Count (10 ³ /mL)	0.68 (0.46 - 0.99)	0.72 (0.46 - 0.93)	0.53 (0.43 - 0.63)	0.0050^{b,c}
Neutrophil Count (10 ³ /mL)	3.46 (2.65 - 5.35)	4.25 (3.32 - 5.23)	2.82 (1.93 - 3.60)	<0.0001^{b,c}
Eosinophil Count (10 ³ /mL)	0.13 (0.07 - 0.26)	0.15 (0.10 - 0.25)	0.10 (0.05 - 0.16)	0.0140^{b,c}
Basophil Count (10 ³ /mL)	0.06 (0.03 - 0.10)	0.06 (0.04 - 0.09)	0.03 (0.02 - 0.04)	<0.0001^{b,c}
Neutrophil to Lymphocyte Ratio	1.14 (0.82 - 1.61)	1.15 (1.03 - 1.56)	1.25 (0.95 - 1.68)	0.6270
IG# (10 ³ /mL)	0.06 (0.03 - 0.09)	0.05 (0.03 - 0.11)	0.01 (0.01 - 0.02)	<0.0001^{b,c}
Nucleated RBC (10 ³ /mL)	0.05 (0.02 - 0.11)	0.07 (0.04 - 0.25)	0.00 (0.00 - 0.01)	<0.0001^{b,c}
Reticulocyte Count (10 ⁶ /mL)	0.15 (0.12 - 0.22)	0.17 (0.12 - 0.27)	0.04 (0.02 - 0.05)	<0.0001^{b,c}
Total Protein (g/L)	87.38 (83.05 - 92.66)	87.96 (81.49 - 95.05)	78.28 (72.75 - 85.01)	<0.0001^{b,c}
Globulin (g/L)	45.50 (42.20 - 50.48)	45.40 (41.08 - 54.40)	36.40 (32.30 - 40.10)	<0.0001^{b,c}
Hemoglobin (g/dL)	9.00 (8.00 - 10.40)	8.65 (7.55 - 9.80)	11.90 (10.80 - 13.20)	<0.0001^{b,c}
Platelet to Lymphocyte Ratio	78.38 (56.40 - 115.50)	104.79 (68.17 - 141.26)	116.35 (85.22 - 151.41)	<0.0001^{b,c}
sNGAL (µg/L)	5.72 (4.76 - 6.52)	6.64 (6.23 - 7.29)	4.47 (3.95 - 4.87)	<0.0001^{a,b,c}
eGFR (mL/min/1.73m ²)	139.07 (96.97 - 183.09)	95.73 (47.80 - 166.43)	120.66 (106.23 - 155.49)	0.0250^a

461 BUN-Blood Urea Nitrogen, WBC- White Cell Count, RBC- Red Blood Count, MCV-Mean Cell Volume, MCH- Mean Cell Haemoglobin, MCHC- Mean Cell
462 Haemoglobin Concentration, PLT- Platelet Count, PDW- Platelet Distribution Width, MPV-Mean Platelet Volume, P-LCR- Platelet- Large Cell Ratio, PCT-
463 Plateletcrit, eGFR-Estimated Glomerular Filtration Rate. ^a: significant when SCD non-nephropathy is compared to SCD nephropathy, ^b: significant when SCD
464 non-nephropathy is compared to Control, ^c: significant when SCD nephropathy is compared to Control. Kruskal Wallis p-values were presented, *p* < 0.05 and
465 bolded means statistically significant


466 **Table 3: Diagnostic performance of sNGAL, Creatinine, Urea, and FAR, in predicting**
 467 **Nephropathy among SCD patients**

Marker	Cut-off	Sensitivity (95% CI)	Specificity (95% CI)	PPV	NPV	LR+	LR-	p-value
sNGAL	>5.72	91.2 (76.1-97.6)	51.4(40.0-62.7)	47.7	92.3	1.88	0.17	<0.0001
Creat	>96.0	47.1(31.5-63.2)	81.4(70.6-88.9)	55.2	76.0	2.534	0.65	0.048
Urea	>3.06	41.2(26.4-57.8)	80.0(69.0-87.8)	50	73.7	2.059	0.735	0.649
FAR	>0.12	26.5(14.5-43.4)	80.0(69.0-87.8)	39.1	69.1	1.324	0.919	0.536

468 Abbreviations: FAR; Fibrinogen-Albumin Ratio, Crea: Creatinine, sNGAL: serum Neutrophil
 469 Gelatinase – Associated Lipocalin, CI: Confidence interval, PPV: Positive predictive value, NPV:
 470 Negative predictive value, LR+: Positive likelihood ratio, LR-: Negative likelihood ratio

471

472



473

474 **Figure 1:** Heat map representing the correlation matrix between sNGAL, eGFR, UACR and the Renal
 475 function Tests (RFT); * Indicates the significance level of $p < 0.05$ of the correlation, $** = p < 0.005$ and $*** = p < 0.0005$.
 476 sNGAL; Neutrophil Gelatinase Associated Lipocalin eGFR; Estimated Glomerular Filtration Rate, UACR; Urine
 477 Albumin-to-creatinine ratio.

478

479

480


481

482

483

484

485



486

487 **Figure 2:** Receiver Operating Curve (ROC) for the various markers in predicting SCD nephropathy

488